Muscle Relaxants in Elderly Patients

  • David R. Bevan
Conference paper


The proportion of elderly patients in the developed world is increasing. Nearly 15 % of the North American population is now more than 65 years old and it is anticipated that the numbers in the group will expand to nearly 20% of the population within the next 30 years. Illnesses such as cancer and vascular disease which are amenable to surgical treatment are common in this age group and, consequently, elderly patients will form an increasingly large part of the anaesthetic population. Thus, it is important that the physiology and pharmacology of aging is are well understood by the anaesthetist to allow a rational approach to anaesthetic management.


Neuromuscular Block Neuromuscular Blocking Drug Recovery Index Elderly Surgical Patient Effect Compartment Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    d’Hollander AA, Luyckx C, Barvais L, De Ville A. Clinical evaluation of atracurium besylate requirement for a stable muscle relaxation during surgery: lack of age-related effects. Anesthesiology 1983;59:237–40.PubMedGoogle Scholar
  2. 2.
    Gariepy LP, Varin F, Donati F, Salib Y, Bevan DR. Influence of aging on the pharmacokinetic and pharmacodynamics of doxacurium. Clin Pharmacol Ther 1993;53:340–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Maddineni VR, McCoy EP, Mirakhur RK, Stanley JC, Lyons SM. Mivacurium in the elderly: comparison of neuromuscular and hemodynamic effects with adults. Anesthesiology 1993;79:A964.Google Scholar
  4. 4.
    Duvaldestin P, Saada J, Berger JL, d’Hollander A, Desmonts JM. Pharmacokinetics, pharmacodynamics, and dose-response relationships of pancuronium in control and elderly subjects. Anesthesiology 1982;56:36–40.PubMedCrossRefGoogle Scholar
  5. 5.
    McLeod K, Hull CJ, Watson MJ. Effects of aging on the pharmacokinetics of pancuronium. Br J Anaesth 1979;51:435–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Somogyi A. Pancuronium plasma clearance and age. Br J Anaesth 1980;52:360.PubMedCrossRefGoogle Scholar
  7. 7.
    Ornstein E, Matteo RS, Schwartz AE, Jamdar SC, Diaz J. Pharmacokinetics and pharmacodynamics of pipecuronium bromide (Arduan) in elderly surgical patients. Anesth Analg 1992;74:841–2.PubMedCrossRefGoogle Scholar
  8. 8.
    Matteo RS, Backus WW, McDaniel DD, Brotherton WP, Abraham R, Diaz J. Pharmacokinetics and pharmacodynamics of d-tubocurarine and metocurine in the elderly. Anesth Analg 1985;64:23–9.PubMedGoogle Scholar
  9. 9.
    Bevan DR, Fiset P, Balendran P, Law-Min JC, Ratcliffe A, Donati F. Pharmacodynamic behaviour of rocuronium in the elderly. Can J Anaesth 1993;40:127–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Matteo RS, Ornstein E, Schwartz AE, Ostapkoviich N, Stone JG. Pharmacokinetics and pharmacodynamics or rocuronium (Org 9426) in elderly surgical patients. Anesth Analg 1993;77:1193–7.PubMedCrossRefGoogle Scholar
  11. 11.
    O’Hara DA, Fragen RJ, Shanks CA. The effects of age on the dose-response curves for vecuronium in adults. Anesthesiology 1985;63:542–4.PubMedCrossRefGoogle Scholar
  12. 12.
    d’Hollander AA, Massaux F, Nevelsteen M, Agoston S. Age-dependent doseresponse relationships of ORG NC 45 in anaesthetized patients. Br J Anaesth 1982;54:653–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Rupp SM, Castognoli K, Fisher DM, Miller RD. Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. Anesthesiology 1987;67:45–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Lien CA, Matteo RS, Ornstein E, Schwartz AE, Diaz J. Distribution, elimination, and action of vecuronium in the elderly. Anesth Analg 1991;73:39–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Koscielniak-Nielsen ZJ, Bevan JC, Popovic V, Baxter MRN, Donati F, Bevan DR. Onset of maximum neuromuscular block following succinylcholine or vecuronium in four age groups. Anesthesiology 1993;79:229–34.PubMedCrossRefGoogle Scholar
  16. 16.
    Marsh RHK, Chimielewski AT, Goat VA. Recovery from pancuronium: a comparison between old and young patients. Anaesthesia 1980;35:1193–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Young WL, Matteo RS, Ornstein E. Duration of action of neostigmine and pyridostigmine in the elderly. Anesth Analg 1988;67:775–8.PubMedGoogle Scholar
  18. 18.
    Young WL, Backus W, Matteo RS, Ornstein E, Diaz J. Pharmacokinetics and pharmacodynamics of neostigmine in the elderly. Anesthesiology 1984;61:A300.CrossRefGoogle Scholar
  19. 19.
    Matteo RS, Young WL, Ornstein E, Schwartz AE, Silverberg PA, Diaz J. Pharmacokinetics and pharmacodynamics of edrophonium in elderly surgical patients. Anesth Analg 1990;71:334–9.PubMedCrossRefGoogle Scholar
  20. 20.
    McCarthy GJ, Cooper R, Stanley JC, Mirakhur RK. Dose-response relationships for neostigmine antagonism of vecuronium-induced neuromuscular blockade in adults and the elderly. Br J Anaesth 1992;69:2813.Google Scholar
  21. 21.
    McCarthy GJ, Mirakhur RK, Boules Z. Dose-response relationships for edrophonium antagonism of vecuronium neuromuscular blockade in young and elderly subjects. Can J Anaesth 1993;40:Google Scholar

Copyright information

© Springer Japan 1995

Authors and Affiliations

  • David R. Bevan
    • 1
  1. 1.Department of AnesthesiologyUniversity of British ColumbiaVancouverCanada

Personalised recommendations